Joanne Curley - 13 May 2021 Form 3 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
Chief Development Officer
Signature
/s/ Joseph R. Young, Attorney-in-Fact
Issuer symbol
VERA
Transactions as of
13 May 2021
Net transactions value
$0
Form type
3
Filing time
13 May 2021, 19:08:33 UTC
Next filing
18 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding VERA Class A Common Stock 23,733 13 May 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VERA Stock Option (right to buy) 13 May 2021 Class A Common Stock 25,891 $6.37 Direct F1
holding VERA Stock Option (right to buy) 13 May 2021 Class A Common Stock 66,022 $2.90 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4 of the shares subject to the option vested on March 12, 2021, and 1/48 of the shares vest monthly thereafter.
F2 1/4 of the shares subject to the option vest on December 16, 2021, and 1/48 of the shares vest monthly thereafter.